Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07314255 (ZL2025) for PTC, I-131, Trop2 is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma (ZL2025) 60 Overall Survival
Clinical Trial NCT07314255 (ZL2025) is an observational study for PTC, I-131, Trop2 that is active, not recruiting. It started on December 18, 2025 with plans to enroll 60 participants. Led by Jiangxi Provincial Cancer Hospital, it is expected to complete by July 1, 2027. The latest data from ClinicalTrials.gov was last updated on January 2, 2026.
Brief Summary
Clinincal data and pathological specimens from patients who had undergone at least one radioactive iodine-131 (^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected (approximately 30-50 cases each in the ^131I treatment-responsive group vs. the ^131I treatment-resistant group). Patients in the ^131I treatment-resistant group underwe...Show More
Official Title
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
Conditions
PTCI-131Trop2Other Study IDs
- ZL2025
- Trop2 and PTC
- 202211013 (Other Grant/Funding Number) (Jiangxi Provincial Health Commission)
NCT ID Number
Start Date (Actual)
2025-12-18
Last Update Posted
2026-01-02
Completion Date (Estimated)
2027-07-01
Enrollment (Estimated)
60
Study Type
Observational
Status
Active, not recruiting
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
RAI responder The ¹³¹I treatment-responsive group was defined as patients who achieved successful radioactive iodine therapy (i.e., lesions disappeared or showed no long-term progression after radioiodine uptake). | radioiodine-131 therapy surgery, tsh inhibition therapy |
RAI nonresponder The ¹³¹I treatment-resistant group was defined as patients meeting any of the following criteria:
No radioiodine uptake in metastatic tissues during the first ¹³¹I treatment, with insignificant decrease or an increase in serum Tg levels before and after therapy; Partial lesions exhibit radioiodine uptake while others showed no uptaking; Progressive metastatic disease despite evident radioiodine uptake. | radioiodine-131 therapy surgery, tsh inhibition therapy |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Tumor size; | Lesion size was determined using CT imaging. Lymph nodes were assessed based on their shortest diameter, while other target lesions were evaluated based on their longest diameter. Each measurable lesion underwent an average measurement derived from a minimum of three readings, with all measurements conducted by the same individual to minimize measurement discrepancies. Response Evaluation Criteria in Solid Tumors (RECIST 1.1) were used to assess treatment response | 6-60 months |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Serological assessment | Including serum thyroglobulin (Tg) and serum anti-thyroglobulin antibody levels (TgAb) in thyrotropin-inhibited states, as well as tumor markers such as CEA | 1-60months |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
(1) Presence of other severe comorbidities; (2) Incomplete clinical or follow-up data.
Jiangxi Provincial Cancer Hospital- 🏛️Lin Zhou
No contact data.
1 Study Locations in 1 Countries
Jiangxi
Jiangxi Cancer Hospital, Nanchang, Jiangxi, 330000, China